Fosamprenavir (Calcium Salt)

Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430) . Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection[1][2].

Product Specifications

CAS Number

[226700-81-8]

Product Name Alternative

GW433908G

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

Drug Intermediate; HIV; HIV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/fosamprenavir-calcium-salt.html

Concentration

10mM

Purity

99.88

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 0.25 mg/mL (ultrasonic; warming)

Smiles

O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP([O-])([O-])=O)CN(S(=O)(C3=CC=C(N)C=C3)=O)CC(C)C.[Ca+2]

Molecular Formula

C25H34CaN3O9PS

Molecular Weight

623.67

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40 (7-8) :1301-10.|[2]Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1 (Suppl 1) :S1-S11.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HIV-1

Citation 01

Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Research Square Print. 2022 May.